title: Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.
abstract: 1. Frusemide was given at a dose of 60 mg as two oral controlled release (CR) formulations and as plain tablets in a randomised, balanced, three way cross over design to 26 healthy volunteers. Urinary volume, and contents of frusemide, sodium, chloride and potassium were measured in samples taken over 24 h. 2. There was a marked difference between the CR formulations on one hand and the plain tablets on the other, in excretion of frusemide and diuresis vs time. The total diuretic/saluretic effect was only marginally lower (19 and 28% respectively, P less than 0.05) after CR compared with plain tablets although the fraction absorbed was markedly decreased (39 and 51% lower, respectively, P less than 0.05), estimated as urinary recovery of frusemide. The total diuresis of the two CR formulations did not differ although the urinary recovery was significantly different (P less than 0.05). 3. The diuretic effect vs frusemide excretion rate showed minimal counter-clockwise hysteresis after plain tablets while the CR formulations produced clockwise hysteresis indicating tolerance. 4. In agreement with the concept of efficiency, the higher diuretic/saluretic effect per amount of excreted frusemide may be a consequence of the slower output of frusemide in urine with the CR formulations compared with plain tablets. The major part of the pharmacological effect was produced with a higher efficiency after CR compared with plain tablets. It should be noted that the pharmacokinetics of a drug and its pharmacodynamic potency independently determine the total response.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Alván
authors.forename: G
authors.initials: G
authors.lastname: Paintaud
authors.forename: S A
authors.initials: SA
authors.lastname: Eckernäs
authors.forename: A
authors.initials: A
authors.lastname: Grahnén
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D002712:Chlorides / Q000652:urine; D003692:Delayed-Action Preparations; D004231:Diuresis / Q000187:drug effects*; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D006801:Humans; D008297:Male; D011188:Potassium / Q000652:urine; D011897:Random Allocation; D012964:Sodium / Q000652:urine
chemical_list: D002712:Chlorides; D003692:Delayed-Action Preparations; D005665:Furosemide; D012964:Sodium; D011188:Potassium